- 中国科学论文统计源期刊
- 中国科技核心期刊
- 美国化学文摘(CA)来源期刊
- 日本科学技术振兴机构数据库(JST)
临床输血与检验 ›› 2022, Vol. 24 ›› Issue (3): 382-391.DOI: 10.3969/j.issn.1671-2587.2022.03.022
邵意涵, 朱培元
收稿日期:2022-04-08
出版日期:2022-06-20
发布日期:2022-06-22
通讯作者:
朱培元,男,硕士研究生导师,（E-mail）zhupy@njucm.edu.cn。
作者简介:邵意涵（1996-）,女,浙江台州人,医学硕士在读,（E-mail）1096204069@qq.com。
基金资助:
Received:2022-04-08
Online:2022-06-20
Published:2022-06-22
摘要： 血小板在人体内不仅参与止血,也是重要的免疫细胞,在维持血管完整性、炎症、调节免疫过程和肿瘤发生发展中起着关键作用,本文总结了血小板发挥免疫调节作用的途径、血小板与白细胞的相互作用、血小板在抗病原体感染中的作用以及血小板在肿瘤发生发展中的作用。从输血医学领域的角度看,不仅要关注输注血小板对于止血的必要性,也应重视血小板免疫调节作用对疾病结局的潜在影响,因此全面了解血小板的免疫学特性对于临床血小板精准输注有重要意义。
中图分类号:
邵意涵, 朱培元. 血小板的免疫学特性研究进展*[J]. 临床输血与检验, 2022, 24(3): 382-391.
| [1] GHOSHAL K,BHATTACHARYYA M.Overview of platelet physiology:its hemostatic and nonhemostatic role in disease pathogenesis[J].Sci World J,2014,2014:781857. [2] LEFRANÇAIS E,ORTIZ-MUÑOZ G,CAUDRILLIER A,et al.The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors[J]. Nature,2017,544(7648):105-109. [3] GAERTNER F,MASSBERG S.Patrolling the vascular borders:platelets in immunity to infection and cancer[J]. Nat Rev Immunol,2019,19(12):747-760. [4] TAKEUCHI O,AKIRA S.Pattern recognition receptors and inflammation[J]. Cell,2010,140(6):805-820. [5] DIB P R B,QUIRINO-TEIXEIRA A C,MERIJ L B,et al. Innate immune receptors in platelets and platelet-leukocyte interactions[J].J Leukoc Biol,2020,108(4):1157-1182. [6] ZAKERI A,RUSSO M.Dual role of toll-like receptors in human and experimental asthma models[J].Front Immunol,2018,9:1027. [7] KOUPENOVA M,CLANCY L,CORKREY H A,et al.Circulating platelets as mediators of immunity,inflammation,and thrombosis[J].Circ Res,2018,122(2):337-351. [8] BERTHET J,DAMIEN P,HAMZEH-COGNASSE H,et al.Human platelets can discriminate between various bacterial LPS isoforms via TLR4 signaling and differential cytokine secretion[J].Clin Immunol,2012,145(3):189-200. [9] KOESSLER J,NIKLAUS M,WEBER K,et al.The role of human platelet preparation for toll-like receptors 2 and 4 related platelet responsiveness[J].TH Open,2019,3(2):e94-e102. [10] EBERMEYER T,COGNASSE F,BERTHELOT P,et al.Platelet innate immune receptors and TLRs:a double-edged sword[J]. Int J Mol Sci,2021,22(15):7894. [11] RAYES J,WATSON S P,NIESWANDT B.Functional significance of the platelet immune receptors GPVI and CLEC-2[J]. J Clin Invest,2019,129(1):12-23. [12] SUNG P S,HUANG T F,HSIEH S L.Extracellular vesicles from CLEC2-activated platelets enhance dengue virus-induced lethality via CLEC5A/TLR2[J]. Nat Commun,2019,10(1):2402. [13] SUNG P S,HSIEH S L.C-type lectins and extracellular vesicles in virus-induced NETosis[J].J Biomed Sci,2021,28(1):46. [14] XIN G,WEI Z L,JI C J,et al.Metformin uniquely prevents thrombosis by inhibiting platelet activation and mtDNA release[J]. Sci Rep,2016,6:36222. [15] HOTTZ E D,LOPES J F,FREITAS C,et al.Platelets mediate increased endothelium permeability in dengue through NLRP3-inflammasome activation[J]. Blood,2013,122(20):3405-3414. [16] VOGEL S,MURTHY P,CUI X D,et al.TLR4-dependent upregulation of the platelet NLRP3 inflammasome promotes platelet aggregation in a murine model of hindlimb ischemia[J].Biochem Biophys Res Commun,2019,508(2):614-619. [17] KIM Y K,SHIN J S,NAHM M H.NOD-like receptors in infection,immunity,and diseases[J].Yonsei Med J,2016,57(1):5-14. [18] BROWN G T,NARAYANAN P,LI W,et al.Lipopolysaccharide stimulates platelets through an IL-1β autocrine loop[J]. J Immunol,2013,191(10):5196-5203. [19] DAVIZON-CASTILLO P,MCMAHON B,AGUILA S,et al.TNF-α-driven inflammation and mitochondrial dysfunction define the platelet hyperreactivity of aging[J]. Blood,2019,134(9):727-740. [20] POZNER R G,URE A E,JAQUENOD DE GIUSTI C,et al. Junín virus infection of human hematopoietic progenitors impairs in vitro proplatelet formation and platelet release via a bystander effect involving type I IFN signaling[J]. PLoS Pathog,2010,6(4):e1000847. [21] BORST O,MÜNZER P,GATIDIS S,et al.The inflammatory chemokine CXC motif ligand 16 triggers platelet activation and adhesion via CXC motif receptor 6-dependent phosphatidylinositide 3-kinase/Akt signaling[J]. Circ Res,2012,111(10):1297-1307. [22] CHATTERJEE M,BORST O,WALKER B,et al.Macrophage migration inhibitory factor limits activation-induced apoptosis of platelets via CXCR7-dependent Akt signaling[J].Circ Res,2014,115(11):939-949. [23] RATH D,CHATTERJEE M,HOLTKAMP A,et al.Evidence of an interaction between TGF-β1 and the SDF-1/CXCR4/CXCR7 axis in human platelets[J]. Thromb Res,2016,144:79-84. [24] CLEMETSON K J,CLEMETSON J M,PROUDFOOT A E,et al.Functional expression of CCR1,CCR3,CCR4,and CXCR4 chemokine receptors on human platelets[J]. Blood,2000,96(13):4046-4054. [25] HARGREAVES C E,ROSE-ZERILLI M J J,MACHADO L R,et al. Fcγ receptors:genetic variation,function,and disease[J].Immunol Rev,2015,268(1):6-24. [26] KERNTKE C,NIMMERJAHN F,BIBURGER M.There is (scientific) strength in numbers:a comprehensive quantitation of fc gamma receptor numbers on human and murine peripheral blood leukocytes[J]. Front Immunol,2020,11:118. [27] PATEL P,MICHAEL J V,NAIK U P,et al.Platelet FcγRⅡA in immunity and thrombosis:adaptive immunothrombosis[J].J Thromb Haemost,2021,19(5):1149-1160. [28] GIANAZZA E,BRIOSCHI M,BAETTA R,et al.Platelets in healthy and disease states:from biomarkers discovery to drug targets identification by proteomics[J]. Int J Mol Sci,2020,21(12):4541. [29] KOUPENOVA M,KEHREL B E,CORKREY H A,et al.Thrombosis and platelets:an update[J]. Eur Heart J,2017,38(11):785-791. [30] DEPPERMANN C,KUBES P.Platelets and infection[J]. Semin Immunol,2016,28(6):536-545. [31] SPAKOVA T,JANOCKOVA J,ROSOCHA J.Characterization and therapeutic use of extracellular vesicles derived from platelets[J].Int J Mol Sci,2021,22(18):9701. [32] CHEN F F,LIAO Z D,PENG D Y,et al.Role of platelet microparticles in blood diseases:future clinical perspectives[J]. Ann Clin Lab Sci,2019,49(2):161-170. [33] QU M Y,ZOU X J,FANG F,et al.Platelet-derived microparticles enhance megakaryocyte differentiation and platelet generation via miR-1915-3p[J].Nat Commun,2020,11(1):4964. [34] LAZAR S,GOLDFINGER L E.Platelets and extracellular vesicles and their cross talk with cancer[J]. Blood,2021,137(23):3192-3200. [35] PUHM F,FLAMAND L,BOILARD E.Platelet extracellular vesicles in COVID-19:potential markers and makers[J]. J Leukoc Biol,2022,111(1):63-74. [36] SCHROTTMAIER W C,MUSSBACHER M,SALZMANN M,et al.Platelet-leukocyte interplay during vascular disease[J]. Atherosclerosis,2020,307:109-120. [37] KAISER R,ESCAIG R,ERBER J,et al.Neutrophil-platelet interactions as novel treatment targets in cardiovascular disease[J].Front Cardiovasc Med,2022,8:824112. [38] CLARK S R,MA A C,TAVENER S A,et al.Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood[J]. Nat Med,2007,13(4):463-469. [39] VAJEN T,KOENEN R R,WERNER I,et al.Blocking CCL5-CXCL4 heteromerization preserves heart function after myocardial infarction by attenuating leukocyte recruitment and NETosis[J].Sci Rep,2018,8(1):10647. [40] PANICKER S R,MEHTA-D'SOUZA P,ZHANG N,et al.Circulating soluble P-selectin must dimerize to promote inflammation and coagulation in mice[J]. Blood,2017,130(2):181-191. [41] STARK K,PHILIPPI V,STOCKHAUSEN S,et al.Disulfide HMGB1 derived from platelets coordinates venous thrombosis in mice[J]. Blood,2016,128(20):2435-2449. [42] LOGUINOVA M,PINEGINA N,KOGAN V,et al.Monocytes of different subsets in complexes with platelets in patients with myocardial infarction[J]. Thromb Haemost,2018,118(11):1969-1981. [43] CARESTIA A,MENA H A,OLEXEN C M,et al. Platelets promote macrophage polarization toward pro-inflammatory phenotype and increase survival of septic mice[J]. Cell Rep,2019,28(4):896-908.e5. [44] FU G,DENG M H,NEAL M D,et al.Platelet-monocyte aggregates:understanding mechanisms and functions in Sepsis[J]. Shock,2021,55(2):156-166. [45] SHI G F,FIELD D J,KO K A,et al.Platelet factor 4 limits Th17 differentiation and cardiac allograft rejection[J]. J Clin Invest,2014,124(2):543-552. [46] MAOUIA A,REBETZ J,KAPUR R,et al.The immune nature of platelets revisited[J].Transfus Med Rev,2020,34(4):209-220. [47] GUO L,SHEN S K,ROWLEY J W,et al.Platelet MHC class I mediates CD8+ T-cell suppression during Sepsis[J]. Blood,2021,138(5):401-416. [48] SPRAGUE D L,ELZEY B D,CRIST S A,et al.Platelet-mediated modulation of adaptive immunity:unique delivery of CD154 signal by platelet-derived membrane vesicles[J]. Blood,2008,111(10):5028-5036. [49] NISHAT S,WUESCHER L M,WORTH R G.Platelets enhance dendritic cell responses against Staphylococcus aureus through CD40-CD40L[J]. Infect Immun,2018,86(9):e00186-e00118. [50] LANGER H F,DAUB K,BRAUN G,et al.Platelets recruit human dendritic cells via Mac-1/JAM-C interaction and modulate dendritic cell function in vitro[J]. Arterioscler Thromb Vasc Biol,2007,27(6):1463-1470. [51] WONG C H Y,JENNE C N,PETRI B,et al. Nucleation of platelets with blood-borne pathogens on Kupffer cells precedes other innate immunity and contributes to bacterial clearance[J]. Nat Immunol,2013,14(8):785-792. [52] HOTTZ E D,BOZZA F A,BOZZA P T.Platelets in immune response to virus and immunopathology of viral infections[J]. Front Med (Lausanne),2018,5:121. [53] LIPPI G,PLEBANI M,HENRY B M.Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections:a meta-analysis[J].Clin Chim Acta,2020,506:145-148. [54] ALTHAUS K,MARINI I,ZLAMAL J,et al.Antibody-induced procoagulant platelets in severe COVID-19 infection[J]. Blood,2021,137(8):1061-1071. [55] BONGIOVANNI D,KLUG M,LAZAREVA O,et al.SARS-CoV-2 infection is associated with a pro-thrombotic platelet phenotype[J].Cell Death Dis,2021,12:50. [56] COMER S P,CULLIVAN S,SZKLANNA P B,et al.COVID-19 induces a hyperactive phenotype in circulating platelets[J].PLoS Biol,2021,19(2):e3001109. [57] ZAID Y,PUHM F,ALLAEYS I,et al.Platelets can associate with SARS-cov-2 RNA and are hyperactivated in COVID-19[J].Circ Res,2020,127(11):1404-1418. [58] CAPPELLANO G,RAINERI D,ROLLA R,et al.Circulating platelet-derived extracellular vesicles are a hallmark of sars-cov-2 infection[J]. Cells,2021,10(1):85. [59] HOTTZ E D,AZEVEDO-QUINTANILHA I G,PALHINHA L,et al. Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19[J]. Blood,2020,136(11):1330-1341. [60] KOUPENOVA M,VITSEVA O,MACKAY C R,et al.Platelet-TLR7 mediates host survival and platelet count during viral infection in the absence of platelet-dependent thrombosis[J]. Blood,2014,124(5):791-802. [61] KOUPENOVA M,CORKREY H A,VITSEVA O,et al.The role of platelets in mediating a response to human influenza infection[J]. Nat Commun,2019,10(1):1780. [62] GARCIA C,COMPAGNON B,POËTTE M,et al. Platelet Versus Megakaryocyte: Who Is the Real Bandleader of Thromboinflammation in Sepsis?[J]. Cells,2022,11(9):1507. [63] GAERTNER F,MASSBERG S.Blood coagulation in immunothrombosis-at the frontline of intravascular immunity[J]. Semin Immunol,2016,28(6):561-569. [64] VERSCHOOR A,NEUENHAHN M,NAVARINI A A,et al.A platelet-mediated system for shuttling blood-borne bacteria to CD8α+ dendritic cells depends on glycoprotein GPIb and complement C3[J].Nat Immunol,2011,12(12):1194-1201. [65] ZUFFEREY A,SPECK E R,MACHLUS K R,et al.Mature murine megakaryocytes present antigen-MHC class I molecules to T cells and transfer them to platelets[J]. Blood Adv,2017,1(20):1773-1785. [66] ELASKALANI O,FALASCA M,MORAN N,et al.The role of platelet-derived ADP and ATP in promoting pancreatic cancer cell survival and gemcitabine resistance[J]. Cancers,2017,9(10):142. [67] CHO M S,NOH K,HAEMMERLE M,et al.Role of ADP receptors on platelets in the growth of ovarian cancer[J]. Blood,2017,130(10):1235-1242. [68] HAEMMERLE M,STONE R L,MENTER D G,et al.The platelet lifeline to cancer:challenges and opportunities[J]. Cancer Cell,2018,33(6):965-983. [69] MICHAEL J V,WURTZEL J G T,MAO G F,et al. Platelet microparticles infiltrating solid tumors transfer miRNAs that suppress tumor growth[J]. Blood,2017,130(5):567-580. [70] XU X R,YOUSEF G M,NI H Y.Cancer and platelet crosstalk:opportunities and challenges for aspirin and other antiplatelet agents[J]. Blood,2018,131(16):1777-1789. [71] TAKEMOTO A,OKITAKA M,TAKAGI S,et al.A critical role of platelet TGF-β release in podoplanin-mediated tumour invasion and metastasis[J]. Sci Rep,2017,7:42186. [72] TANG M L,JIANG L,LIN Y Y,et al.Platelet microparticle-mediated transfer of miR-939 to epithelial ovarian cancer cells promotes epithelial to mesenchymal transition[J]. Oncotarget,2017,8(57):97464-97475. [73] HWANG B O,PARK S Y,CHO E S,et al.Platelet CLEC2-podoplanin axis as a promising target for oral cancer treatment[J]. Front Immunol,2021,12:807600. [74] MAMMADOVA-BACH E,ZIGRINO P,BRUCKER C,et al.Platelet integrin α 6 β 1 controls lung metastasis through direct binding to cancer cell-derived ADAM9[J]. JCI Insight,2016,1(14):e88245. [75] BOUCHARABA A,SERRE C M,GRÈS S,et al. Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer[J]. J Clin Invest,2004,114(12):1714-1725. [76] MAURER S,FERRARI DE ANDRADE L.NK cell interaction with platelets and myeloid cells in the tumor milieu[J]. Front Immunol,2020,11:608849. [77] CLUXTON C D,SPILLANE C,O'TOOLE S A,et al. Suppression of Natural Killer cell NKG2D and CD226 anti-tumour cascades by platelet cloaked cancer cells:implications for the metastatic cascade[J]. PLoS One,2019,14(3):e0211538. [78] PLACKE T,ÖRGEL M,SCHALLER M,et al.Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells[J]. Cancer Res,2012,72(2):440-448. [79] BOUCHARD A,COLLIN B,GARRIDO C,et al.GARP:a key target to evaluate tumor immunosuppressive microenvironment[J]. Biology,2021,10(9):836. [80] ZIMMER N,KREBS F K,ZIMMER S,et al.Platelet-derived GARP induces peripheral regulatory T cells-potential impact on T cell suppression in patients with melanoma-associated thrombocytosis[J]. Cancers,2020,12(12):3653. [81] BURNOUF T,ELEMARY M,RADOSEVIC J,et al.Platelet transfusion in thrombocytopenic cancer patients:sometimes justified but likely insidious[J]. Transfus Apher Sci,2017,56(3):305-309. [82] WOOD B,PADULA M P,MARKS D C,et al.Cryopreservation alters the immune characteristics of platelets[J]. Transfusion,2021,61(12):3432-3442. |
| [1] | 中国输血协会人类组织抗原专业委员会, 中国输血协会免疫血液学专业委员会. 免疫性血小板输注无效的判定及临床实践专家共识*[J]. 临床输血与检验, 2022, 24(3): 273-278. |
| [2] | 中国人体健康科技促进会妇科内分泌和生育力促进分会, 中国女医师协会输血专业委员会. 自体富血小板纤维蛋白（PRF）治疗宫腔粘连专家共识[J]. 临床输血与检验, 2022, 24(3): 279-284. |
| [3] | 牛思颖, 徐嘉婕, 徐梦瑶, 张议丹, 夏利军, 江淼. 改良型平板流动小室的研制及其在病理血管条件下血小板黏附功能检测中的应用*[J]. 临床输血与检验, 2022, 24(3): 308-314. |
| [4] | 王静, 胡艳, 朱曼, 胡芮维, 张洪为, 黄远帅. 四盐酸精胺抑制血小板活化的初步研究*[J]. 临床输血与检验, 2022, 24(3): 315-319. |
| [5] | 林放, 周谋, 李文丹, 孙宇, 骆美良, 单桂秋. 富血小板纤维蛋白对金黄色葡萄球菌-大肠杆菌混合菌的体外抑菌效果研究*[J]. 临床输血与检验, 2022, 24(3): 320-324. |
| [6] | 鲁大鹏, 王保龙. 血清miRNAs作为潜在肝癌诊断标志物的临床价值研究*[J]. 临床输血与检验, 2022, 24(3): 343-348. |
| [7] | 杨慕坤, 王子君, 崔广霞, 陈麟凤, 白文佩. 富血小板纤维蛋白对宫腔粘连创面修复的影响研究*[J]. 临床输血与检验, 2022, 24(3): 363-368. |
| [8] | 苏贤, 李艳宏, 阎少多. 血小板促进肝再生的作用机制及其研究进展*[J]. 临床输血与检验, 2022, 24(3): 392-398. |
| [9] | 杨惠宽, 吴千羽, 张嘉仪, 陈小洁, 苑召虎, 魏亚明. miRNA作为血小板储存损伤标志物研究初探*[J]. 临床输血与检验, 2022, 24(2): 176-181. |
| [10] | 李正业, 王浩, 史玮, 高海燕, 马现君. 自体血小板分离回输技术对于不同血小板水平的主动脉夹层患者成分血输注量的影响研究[J]. 临床输血与检验, 2022, 24(2): 207-210. |
| [11] | 刘琴, 徐春芬, 宋婕, 谢松丽, 陈涵薇, 胡红兵. 输注不同治疗剂量血小板在56例急性淋巴细胞白血病患儿中的临床观察*[J]. 临床输血与检验, 2022, 24(2): 218-221. |
| [12] | 黎海燕, 李保才, 李丽君. 血小板无力症的诊治新进展*[J]. 临床输血与检验, 2022, 24(2): 244-248. |
| [13] | 王璐, 姚春艳. 冷藏血小板输注后的清除机制*[J]. 临床输血与检验, 2022, 24(2): 249-252. |
| [14] | 董玉芳, 李萌, 陈雪. 血小板类产品细菌污染的预防、控制相关研究进展[J]. 临床输血与检验, 2022, 24(2): 258-263. |
| [15] | 罗开云, 王淑君, 毛平平, 孙杨子, 齐清, 栾建凤. 不同保存方式对PRP相关生长因子影响的研究*[J]. 临床输血与检验, 2022, 24(1): 70-73. |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||
